Novel uses of rituximab;Nouvelles indications du rituximab

Revue du Praticien

Volumn 63, Issue 10, 2013, Pages 1349-1353

  Frenzel, Laurent ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

RITUXIMAB;

CHRONIC LYMPHATIC LEUKEMIA; DRUG EFFICACY; DRUG MARKETING; EPSTEIN BARR VIRUS INFECTION; FOLLICULAR LYMPHOMA; FRANCE; HEMOLYTIC ANEMIA; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; KIDNEY TRANSPLANTATION; LARGE CELL LYMPHOMA; MULTIPLE SCLEROSIS; PROPHYLAXIS; REVIEW; RHEUMATOID ARTHRITIS; TREATMENT INDICATION; VASCULITIS;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; AUTOIMMUNE DISEASES; GRAFT REJECTION; HEMATOLOGIC DISEASES; HUMANS; LYMPHOPROLIFERATIVE DISORDERS; ORGAN TRANSPLANTATION;

EID: 84892597472     PISSN: 00352640     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Carson KR, Focosi D, Major EO, et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab : a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol 2009;10:816-24.
2. Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients : a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009;113:4834-40.
3. Godeau B, Porcher R, Fain O, et al. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura : results of a prospective multicenter phase 2 study Blood 2008;112:999-1004
4. Auger S, Duny Y, Rossi JF, Quittet P. Rituximab before splenectomy in adults with primary idiopathic thrombocytopenic purpura, a meta-analysis. Br J Haematol 2012;158:386-98.
5. Patel VL, Mahévas M, Lee SY, et al. Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia Blood 2012;119:5989-95
6. Stasi R, Stipa E, Masi M, et al. Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura. Am. J. Med 1995;98:436-42.
7. Arnold DM, Heddle NM, Carruthers J, et al. A pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomized patients with immune thrombocytopenia Blood 2012;119:1356-62.
8. Stasi R, Pagano A, Stipa E, Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 2001;98:952-7.
9. Peñalver FJ, Alvarez-Larrán A, Díez-Martin JL, et al. Rituximab is an effective and safe therapeutic alternative in adults with refractory and severe autoimmune hemolytic anemia. Ann Hematol 2010;89:1073-80.
10. Berentsen S, Randen U, Vågan AM, et al. High response rate and durable remissions following fludarabine and rituximab combination therapy for chronic cold agglutinin disease Blood 2010;116:3180-4.
11. Barcellini W, Zaja F, Zaninoni A, et al. Low-dose rituximab in adult patients with idiopathic autoimmune hemolytic anemia clinical efficacy and biologic studies Blood 2012;119:3691-7.
12. Scully M, McDonald V, Cavenagh J, et al. A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura Blood 2011;118:1746-53.
13. Froissart A, Buffet M, Veyradier A, et al. Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center. Crit Care Med 2012;40:104-11.
14. Collins P, Baudo F, Knoebl P, et al. Immunosuppression for acquired hemophilia A : results from the European Acquired Haemophilia Registry (EACH2). Blood 2012;120:47-55.
15. Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis N Engl J Med 2010;363:221-32
16. Looney RJ, Anolik JH, Campbell D, et al. B cell depletion as a novel treatment for systemic lupus erythematosus. a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004;50:2580-9.
17. Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus, the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial Arthritis Rheum 2010;62:222-33.
18. St Clair EW, Levesque MC, Prak ETL, et al. Rituximab therapy for primary Sjögren's syndrome an open-label clinical trial and mechanistic analysis. Arthritis Rheum 2013;65:1097-106
19. Gottenberg JE, Cinquetti G, Larroche C, et al. Efficacy of rituximab in systemic manifestations of primary Sjogren's syndrome: results in 78 patients of the Autoimmune and rituximab registry. Ann. Rheum. Dis 2013;72:1026-31.
20. Smith V, Van Praet JT, Vandooren B, et al. Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Ann. Rheum. Dis 2010;69:193-7.
21. Lafyatis R, Kissin E, York M, et al. B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum 2009;60:578-83
22. Oddis CV, Reed AM, Aggarwal R, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis : a randomized, placebo-phase trial Arthritis Rheum 2013;65:314-24
23. Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008;358:676-688
24. Hawker K, O'Connor P, Freedman MS, et al. Rituximab in patients with primary progressive multiple sclerosis. results of a randomized double-blind placebo-controlled multicenter trial Ann. Neurol 2009;66:460-71.
25. Bahn RS. Graves'ophthalmopathy. N Engl J Med 2010;362:726-38
26. Joly P, Mouquet H, Roujeau JC, et al. A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med 2007;357:545-52.
27. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, et al. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 2009;361:2143-52.
28. Zarkhin V, Li L, Kambham N, Sigdel T, Salvatierra O, Sarwal MM. A randomized, prospective trial of rituximab for acute rejection in pediatric renal transplantation. Am J Transplant 2008;8:2607-17.
29. Tydén G, Genberg H, Tollemar J, et al. A randomized, doubleblind, placebo-controlled, study of single-dose rituximab as induction in renal transplantation Transplant 2009;87:1325-9.
30. Blaes AH, Peterson BA, Bartlett N, Dunn DL, Morrison VA. Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation results of a phase II trial. Cancer 2005;104:1661-7.
31. Oertel SHK, Verschuuren E, Reinke P, et al. Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD). Am J Transplant 2005;5:2901-6